The Potential Role of Renal Denervation in the Management of Heart Failure.
Kameel KassabRonak SoniAdnan KassierTim A FischellPublished in: Journal of clinical medicine (2022)
Sympathetic nervous system activation in patients with heart failure is one of the main pathophysiologic mechanisms associated with the worse outcomes. Pharmacotherapies targeting neurohormonal activation have been at the center of heart failure management. Despite the advancement of therapies and the available treatments, heart failure continues to have an overall poor prognosis. Renal denervation was originally developed to lower systemic blood pressure in patients with poorly controlled hypertension, by modulating sympathetic outflow. However, more recently, multiple studies have investigated the effect of renal denervation in heart failure patients with both preserved (HFpEF) and reduced ejection fractions (HFrEF). This paper provides an overview of the potential effect of renal denervation in altering the various pathophysiologic, sympathetically mediated pathways that contribute to heart failure, and reviews the literature that supports its future use in those patients.
Keyphrases
- heart failure
- poor prognosis
- blood pressure
- left ventricular
- acute heart failure
- long non coding rna
- atrial fibrillation
- cardiac resynchronization therapy
- systematic review
- end stage renal disease
- newly diagnosed
- type diabetes
- risk assessment
- chronic kidney disease
- heart rate
- mass spectrometry
- human health
- insulin resistance
- blood glucose